메뉴 건너뛰기




Volumn 49, Issue 18, 2013, Pages 3936-3944

Synergistic inhibition of ovarian cancer cell growth by combining selective PI3K/mTOR and RAS/ERK pathway inhibitors

Author keywords

Ovarian cancer; PI3Kinase; RAS ERK pathway; Therapeutics

Indexed keywords

2 AMINO 8 [4 (2 HYDROXYETHOXY)CYCLOHEXYL] 6 (6 METHOXYPYRIDIN 3 YL) 4 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; PF 04691502; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; RAS PROTEIN; UNCLASSIFIED DRUG;

EID: 84887994218     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2013.08.007     Document Type: Article
Times cited : (72)

References (40)
  • 2
    • 79959838081 scopus 로고    scopus 로고
    • Integrated genomic analyses of ovarian carcinoma
    • TCGA
    • TCGA Integrated genomic analyses of ovarian carcinoma Nature 474 2011 609 615
    • (2011) Nature , vol.474 , pp. 609-615
  • 3
    • 0037454224 scopus 로고    scopus 로고
    • Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma
    • G. Singer, R. Oldt, Y. Cohen, B.G. Wang, D. Sidransky, and R.J. Kurman Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
    • (2003) J Natl Cancer Inst , vol.95 , pp. 484-486
    • Singer, G.1    Oldt, R.2    Cohen, Y.3    Wang, B.G.4    Sidransky, D.5    Kurman, R.J.6
  • 5
    • 67649440886 scopus 로고    scopus 로고
    • The biology of ovarian cancer: New opportunities for translation
    • R.C. Bast Jr., B. Hennessy, and G.B. Mills The biology of ovarian cancer: new opportunities for translation Nat Rev Cancer 9 2009 415 428
    • (2009) Nat Rev Cancer , vol.9 , pp. 415-428
    • Bast, Jr.R.C.1    Hennessy, B.2    Mills, G.B.3
  • 6
    • 79960716001 scopus 로고    scopus 로고
    • Akt signalling in health and disease
    • I. Hers, E.E. Vincent, and J.M. Tavare Akt signalling in health and disease Cell Signal 23 2011 1515 1527
    • (2011) Cell Signal , vol.23 , pp. 1515-1527
    • Hers, I.1    Vincent, E.E.2    Tavare, J.M.3
  • 7
    • 0242637318 scopus 로고    scopus 로고
    • MTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF
    • K.M. Hannan, Y. Brandenburger, A. Jenkins, K. Sharkey, A. Cavanaugh, and L. Rothblum MTOR-dependent regulation of ribosomal gene transcription requires S6K1 and is mediated by phosphorylation of the carboxy-terminal activation domain of the nucleolar transcription factor UBF Mol Cell Biol 23 2003 8862 8877
    • (2003) Mol Cell Biol , vol.23 , pp. 8862-8877
    • Hannan, K.M.1    Brandenburger, Y.2    Jenkins, A.3    Sharkey, K.4    Cavanaugh, A.5    Rothblum, L.6
  • 8
    • 32044465506 scopus 로고    scopus 로고
    • TOR signaling in growth and metabolism
    • S. Wullschleger, R. Loewith, and M.N. Hall TOR signaling in growth and metabolism Cell 124 2006 471 484
    • (2006) Cell , vol.124 , pp. 471-484
    • Wullschleger, S.1    Loewith, R.2    Hall, M.N.3
  • 9
    • 0037264633 scopus 로고    scopus 로고
    • Signalling pathways in cancer therapy
    • J. Downward, and R.A.S. Targeting Signalling pathways in cancer therapy Nat Rev Cancer 3 2003 11 22
    • (2003) Nat Rev Cancer , vol.3 , pp. 11-22
    • Downward, J.1    Targeting, R.A.S.2
  • 10
    • 38949183695 scopus 로고    scopus 로고
    • Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy
    • B.B. Friday, and A.A. Adjei Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy Clin Cancer Res 14 2008 342 346
    • (2008) Clin Cancer Res , vol.14 , pp. 342-346
    • Friday, B.B.1    Adjei, A.A.2
  • 11
    • 79951928689 scopus 로고    scopus 로고
    • Novel mitogen-activated protein kinase kinase inhibitors
    • M.S. Chapman, and J.N. Miner Novel mitogen-activated protein kinase kinase inhibitors Expert Opin Investig Drugs 20 2011 209 220
    • (2011) Expert Opin Investig Drugs , vol.20 , pp. 209-220
    • Chapman, M.S.1    Miner, J.N.2
  • 13
    • 4544343980 scopus 로고    scopus 로고
    • Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies
    • O.J. Shah, Z. Wang, and T. Hunter Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies Curr Biol 14 2004 1650 1656
    • (2004) Curr Biol , vol.14 , pp. 1650-1656
    • Shah, O.J.1    Wang, Z.2    Hunter, T.3
  • 14
    • 79851513692 scopus 로고    scopus 로고
    • Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design
    • H. Cheng, S. Bagrodia, S. Bailey, M. Edwards, J. Hoffman, and Q. Hu Discovery of the highly potent PI3K/mTOR dual inhibitor PF-04691502 through structure based drug design Med Chem Commun 1 2010 139 144
    • (2010) Med Chem Commun , vol.1 , pp. 139-144
    • Cheng, H.1    Bagrodia, S.2    Bailey, S.3    Edwards, M.4    Hoffman, J.5    Hu, Q.6
  • 15
    • 84887990348 scopus 로고    scopus 로고
    • < http://www.clinicaltrials.gov >.
  • 16
    • 77949766280 scopus 로고    scopus 로고
    • Phase i pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers
    • P.M. LoRusso, S.S. Krishnamurthi, J.J. Rinehart, L.M. Nabell, L. Malburg, and P.B. Chapman Phase I pharmacokinetic and pharmacodynamic study of the oral MAPK/ERK kinase inhibitor PD-0325901 in patients with advanced cancers Clin Cancer Res 16 2010 1924 1937
    • (2010) Clin Cancer Res , vol.16 , pp. 1924-1937
    • Lorusso, P.M.1    Krishnamurthi, S.S.2    Rinehart, J.J.3    Nabell, L.M.4    Malburg, L.5    Chapman, P.B.6
  • 17
    • 17144418558 scopus 로고    scopus 로고
    • Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy
    • E.M. Wallace, J.P. Lyssikatos, T. Yeh, J.D. Winkler, and K. Koch Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy Curr Top Med Chem 5 2005 215 229
    • (2005) Curr Top Med Chem , vol.5 , pp. 215-229
    • Wallace, E.M.1    Lyssikatos, J.P.2    Yeh, T.3    Winkler, J.D.4    Koch, K.5
  • 18
    • 33847095086 scopus 로고    scopus 로고
    • Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration
    • A.P. Brown, T.C. Carlson, C.M. Loi, and M.J. Graziano Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration Cancer Chemother Pharmacol 59 2007 671 679
    • (2007) Cancer Chemother Pharmacol , vol.59 , pp. 671-679
    • Brown, A.P.1    Carlson, T.C.2    Loi, C.M.3    Graziano, M.J.4
  • 19
    • 76549129820 scopus 로고    scopus 로고
    • Drug combination studies and their synergy quantification using the Chou-Talalay method
    • T.C. Chou Drug combination studies and their synergy quantification using the Chou-Talalay method Cancer Res 70 2010 440 446
    • (2010) Cancer Res , vol.70 , pp. 440-446
    • Chou, T.C.1
  • 20
    • 18744369640 scopus 로고    scopus 로고
    • Use of within-array replicate spots for assessing differential expression in microarray experiments
    • G.K. Smyth, J. Michaud, and H.S. Scott Use of within-array replicate spots for assessing differential expression in microarray experiments Bioinformatics 21 2005 2067 2075
    • (2005) Bioinformatics , vol.21 , pp. 2067-2075
    • Smyth, G.K.1    Michaud, J.2    Scott, H.S.3
  • 21
    • 80051584382 scopus 로고    scopus 로고
    • In vivo activity of combined PI3K/mTOR and MEK inhibition in a KrasG12D;Pten deletion mouse model of ovarian cancer
    • K.M. Kinross, D.V. Brown, M. Kleinschmidt, S. Jackson, J. Christensen, and C. Cullinane In vivo activity of combined PI3K/mTOR and MEK inhibition in a KrasG12D;Pten deletion mouse model of ovarian cancer Mol Cancer Ther 10 2011 1440 1449
    • (2011) Mol Cancer Ther , vol.10 , pp. 1440-1449
    • Kinross, K.M.1    Brown, D.V.2    Kleinschmidt, M.3    Jackson, S.4    Christensen, J.5    Cullinane, C.6
  • 22
  • 23
    • 68049085887 scopus 로고    scopus 로고
    • In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
    • K.P. Hoeflich, C. O'Brien, Z. Boyd, G. Cavet, S. Guerrero, and K. Jung In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models Clin Cancer Res 15 2009 4649 4664
    • (2009) Clin Cancer Res , vol.15 , pp. 4649-4664
    • Hoeflich, K.P.1    O'Brien, C.2    Boyd, Z.3    Cavet, G.4    Guerrero, S.5    Jung, K.6
  • 25
    • 11144356304 scopus 로고    scopus 로고
    • S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway
    • M. Pende, S.H. Um, V. Mieulet, M. Sticker, V.L. Goss, and J. Mestan S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5′-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway Mol Cell Biol 24 2004 3112 3124
    • (2004) Mol Cell Biol , vol.24 , pp. 3112-3124
    • Pende, M.1    Um, S.H.2    Mieulet, V.3    Sticker, M.4    Goss, V.L.5    Mestan, J.6
  • 26
    • 2342624080 scopus 로고    scopus 로고
    • EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy
    • J.G. Paez, P.A. Janne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
    • (2004) Science , vol.304 , pp. 1497-1500
    • Paez, J.G.1    Janne, P.A.2    Lee, J.C.3    Tracy, S.4    Greulich, H.5    Gabriel, S.6
  • 27
    • 51849111524 scopus 로고    scopus 로고
    • NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations
    • V. Serra, B. Markman, M. Scaltriti, P.J.A. Eichhorn, V. Valero, and M. Guzman NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations Cancer Res 68 2008 8022 8030
    • (2008) Cancer Res , vol.68 , pp. 8022-8030
    • Serra, V.1    Markman, B.2    Scaltriti, M.3    Eichhorn, P.J.A.4    Valero, V.5    Guzman, M.6
  • 28
    • 58249120506 scopus 로고    scopus 로고
    • Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
    • N.T. Ihle, R. Lemos Jr., P. Wipf, A. Yacoub, C. Mitchell, and D. Siwak Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance Cancer Res. 69 2009 143 150
    • (2009) Cancer Res. , vol.69 , pp. 143-150
    • Ihle, N.T.1    Lemos, Jr.R.2    Wipf, P.3    Yacoub, A.4    Mitchell, C.5    Siwak, D.6
  • 29
    • 52449092107 scopus 로고    scopus 로고
    • Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling
    • Q.B. She, S. Chandarlapaty, Q. Ye, J. Lobo, K.M. Haskell, and K.R. Leander Breast tumor cells with PI3K mutation or HER2 amplification are selectively addicted to Akt signaling PLoS One 3 2008 e3065
    • (2008) PLoS One , vol.3 , pp. 3065
    • She, Q.B.1    Chandarlapaty, S.2    Ye, Q.3    Lobo, J.4    Haskell, K.M.5    Leander, K.R.6
  • 30
    • 77953761653 scopus 로고    scopus 로고
    • Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: In silico and biological evaluations
    • S. Dan, M. Okamura, M. Seki, K. Yamazaki, H. Sugita, and M. Okui Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations Cancer Res 70 2010 4982 4994
    • (2010) Cancer Res , vol.70 , pp. 4982-4994
    • Dan, S.1    Okamura, M.2    Seki, M.3    Yamazaki, K.4    Sugita, H.5    Okui, M.6
  • 31
    • 77954592048 scopus 로고    scopus 로고
    • Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines
    • E.B. Garon, R.S. Finn, W. Hosmer, J. Dering, C. Ginther, and S. Adhami Identification of common predictive markers of in vitro response to the Mek inhibitor selumetinib (AZD6244; ARRY-142886) in human breast cancer and non-small cell lung cancer cell lines Mol Cancer Ther 9 2010 1985 1994
    • (2010) Mol Cancer Ther , vol.9 , pp. 1985-1994
    • Garon, E.B.1    Finn, R.S.2    Hosmer, W.3    Dering, J.4    Ginther, C.5    Adhami, S.6
  • 33
    • 66449132288 scopus 로고    scopus 로고
    • KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer
    • J.J. Yeh, E.D. Routh, T. Rubinas, J. Peacock, T.D. Martin, and X.J. Shen KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer Mol Cancer Ther 8 2009 834 843
    • (2009) Mol Cancer Ther , vol.8 , pp. 834-843
    • Yeh, J.J.1    Routh, E.D.2    Rubinas, T.3    Peacock, J.4    Martin, T.D.5    Shen, X.J.6
  • 34
    • 57449092484 scopus 로고    scopus 로고
    • KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer
    • N. Nakayama, K. Nakayama, S. Yeasmin, M. Ishibashi, A. Katagiri, and K. Iida KRAS or BRAF mutation status is a useful predictor of sensitivity to MEK inhibition in ovarian cancer Br J Cancer 99 2008 2020 2028
    • (2008) Br J Cancer , vol.99 , pp. 2020-2028
    • Nakayama, N.1    Nakayama, K.2    Yeasmin, S.3    Ishibashi, M.4    Katagiri, A.5    Iida, K.6
  • 35
    • 51349100763 scopus 로고    scopus 로고
    • A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition
    • N.E. Torbett, A. Luna-Moran, Z.A. Knight, A. Houk, M. Moasser, and W. Weiss A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition Biochem J 415 2008 97 110
    • (2008) Biochem J , vol.415 , pp. 97-110
    • Torbett, N.E.1    Luna-Moran, A.2    Knight, Z.A.3    Houk, A.4    Moasser, M.5    Weiss, W.6
  • 36
    • 57349194139 scopus 로고    scopus 로고
    • Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
    • J.A. Engelman, L. Chen, X. Tan, K. Crosby, A.R. Guimaraes, and R. Upadhyay Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers Nat Med 14 2008 1351 1356
    • (2008) Nat Med , vol.14 , pp. 1351-1356
    • Engelman, J.A.1    Chen, L.2    Tan, X.3    Crosby, K.4    Guimaraes, A.R.5    Upadhyay, R.6
  • 38
    • 34248563290 scopus 로고    scopus 로고
    • The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition
    • S. Meloche, and J. Pouyssegur The ERK1/2 mitogen-activated protein kinase pathway as a master regulator of the G1- to S-phase transition Oncogene 26 2007 3227 3239
    • (2007) Oncogene , vol.26 , pp. 3227-3239
    • Meloche, S.1    Pouyssegur, J.2
  • 39
    • 81055149891 scopus 로고    scopus 로고
    • PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity
    • J. Yuan, P.P. Mehta, M.-J. Yin, S. Sun, A. Zou, and J. Chen PF-04691502, a potent and selective oral inhibitor of PI3K and mTOR kinases with antitumor activity Mol Cancer Ther 10 2011 2189 2199
    • (2011) Mol Cancer Ther , vol.10 , pp. 2189-2199
    • Yuan, J.1    Mehta, P.P.2    Yin, M.-J.3    Sun, S.4    Zou, A.5    Chen, J.6
  • 40
    • 84887991788 scopus 로고    scopus 로고
    • MTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling
    • Rodrik-Outmezguine, and Rosen mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling Cancer Discov 2011 1 13
    • (2011) Cancer Discov , pp. 1-13
    • Rodrik-Outmezguine1    Rosen2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.